APM Marketplace
The first diagnosed case of Ebola in the United States reveals a truth people in developing countries know all too well: There is little incentive for drug manufacturers to develop vaccines and drugs for diseases that affect the poor. “If there are a million consumers and each of them would be willing to pay $1,000 for a drug, that translates into a billion-dollar potential market,” he says economist
Frank Lichtenberg; That is in no way the Ebola market.
Published on October 02, 2014 07:29